Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FTY720 in Kidney Transplant Recipients
NCT00099736Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2003
- Primary completion
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fingolimod in kidney transplant rejection (3 arms), sponsored by Novartis. Primary endpoint: Incidence of biopsy-proven acute rejection, graft loss, death, or lost to follow-up at 12 months. Started May 2003; status: completed.
02
Drugs
fingolimod
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00099736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00099736.